Hoenle AG (ETR:HNL)
Germany · Delayed Price · Currency is EUR | Market Cap | 45.46M +1.9% |
| Revenue (ttm) | 92.90M -3.7% |
| Net Income | -2.91M |
| EPS | -0.48 |
| Shares Out | 6.06M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,745 |
| Open | 7.40 |
| Previous Close | 7.46 |
| Day's Range | 7.40 - 7.56 |
| 52-Week Range | 6.48 - 10.40 |
| Beta | 1.47 |
| Analysts | Strong Buy |
| Price Target | 16.33 (+117.73%) |
| Earnings Date | Dec 8, 2026 |
About Hoenle AG
Hoenle AG develops, manufactures, and distributes industrial UV technologies and systems in Germany and internationally. It operates through three segments: Adhesive Systems, Curing, and Disinfection. The Adhesives Systems segment offers industrial adhesives, as well as supplies adhesive curing systems used for consumer electronics, automotive, optics and opto-electronics, and curing of adhesives applications. The Curing segment sells equipment for surface drying and curing paints, varnishes, and other coatings for printing, packaging printing,... [Read more]
Financial Performance
In fiscal year 2025, Hoenle AG's revenue was 93.68 million, a decrease of -5.11% compared to the previous year's 98.73 million. Losses were -3.17 million, -76.15% less than in 2024.
Financial StatementsAnalyst Summary
According to 3 analysts, the average rating for HNL stock is "Strong Buy." The 12-month stock price target is €16.33, which is an increase of 117.73% from the latest price.
News
Hoenle AG Earnings Call Transcript: Q3 2026
Revenue remained stable year-over-year, with EBITDA up 26% to EUR 4.5 million, driven by Adhesive Systems and Disinfection growth. Curing segment remains challenged but shows signs of recovery, with full-year revenue expected at EUR 92–95 million and EBITDA at EUR 5–6 million.
Hoenle AG Quarterly report: Q3 2026
Hoenle AG has published its Q3 2026 quarterly earnings report on August 18, 2026.
Hoenle AG Slides: Q3 2026
Hoenle AG has posted slides in relation to its Q3 2026 quarterly earnings report, which was published on August 18, 2026.
Hoenle AG Earnings Call Transcript: Q2 2026
Revenue and EBITDA improved sequentially, with Adhesive and Disinfection units showing growth, while Curing faced continued challenges from weak investment and customer insolvency. Full-year guidance is maintained, but expectations are toward the lower end due to market uncertainty.
Hoenle AG Quarterly report: Q2 2026
Hoenle AG has published its Q2 2026 quarterly earnings report on May 19, 2026.
Hoenle AG Slides: Company presentation
Hoenle AG has posted slides in relation to its latest quarterly earnings report, which was published on April 7, 2026.
Hoenle AG Earnings Call Transcript: Q1 2026
Q1 sales and EBITDA were flat to slightly down year-over-year, with Disinfection showing strong growth while Curing lagged due to weak investment demand. Full-year guidance is maintained, with expectations for stronger performance in the second half and ongoing cost control.
Hoenle AG Quarterly report: Q1 2026
Hoenle AG has published its Q1 2026 quarterly earnings report on February 24, 2026.
Hoenle AG Slides: Q1 2026
Hoenle AG has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on February 24, 2026.
Hoenle AG Annual report: Q4 2025
Hoenle AG has published its Q4 2025 annual report on January 29, 2026.
Mixed Q3, FY guidance lowered but prospect remain attractive
Dr. Hönle reported Q3 revenue down 5.5% to €22.4m amid weak demand, particularly in adhesives. New FY24/25 guidance lowered; BUY with €16 price target. Jetzt den vollständigen Artikel lesen